SAO PAULO (Reuters) – Danish drugmaker Novo Nordisk will definitely spend 864 million reais ($ 158.2 million) to overtake a plant in Brazil in control of draining 1 / 4 of its insulin manufacturing around the globe, the corporate acknowledged on Friday.
The funds will definitely improve the Montes Claros manufacturing facility, within the southeastern state of Minas Gerais, and apply lasting jobs there, Novo Nordisk acknowledged in a declaration.
The producer of Ozempic and Wegovy, which have really blown up in attraction for his or her utilization as weight-loss medicines, made the information public as Brazilian President Luiz Inacio Lula da Silva fulfilled beforehand within the day with Queen Mary Donaldson of Denmark, the Brazilian federal authorities acknowledged in a declaration.
($ 1 = 5.4627 reais)
(Reporting by Andre Romani and Paula Arend Laier; Editing by Gabriel Araujo and Kylie Madry)
